NERD, GERD, and beyond: A consideration of the expanding spectrum of gastroesophageal reflux disease

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL.2, 2007, Pages

  Quigley, Eamonn M M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork   (Ireland)

Author keywords

Esophagus; GERD

Indexed keywords

ACID; PROTON PUMP INHIBITOR;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; DEMOGRAPHY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; MICROSCOPY; NONEROSIVE REFLUX DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 34250778944     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3180329029     Document Type: Conference Paper

References (48)

1. Fass R, Fennerty MB, Vakil N. Non-erosive reflux disease (NERD) - current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
2. Quigley EM. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol. 2001;13(suppl 1): S13-S18.
3. Malfertheiner P, Fass R, Quigley EM, et al. Review article: from gastrin to gastro-oesophageal reflux disease - a century of acid suppression. Aliment Pharmacol Ther. 2006;23:683-690.
4. Quigley EM, DiBaise JK. Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. Dig Liver Dis. 2001;33:523-527.
5. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371-376.
6. Ronkainen J, Aro P, Storskrubb T, et al. Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population - the Kalixanda study. Aliment Pharmacol Ther. 2006;23:1725-1733.
7. Mishima I, Adachi K, Arima N, et al. Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40:1005-1009.
8. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767-776.
9. Fennerty MB, Johnson DA. Heartburn severity does not predict disease severity in patients with erosive esophagitis. Med Gen Med. 2006;8:6.
10. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
11. Klesslich R, Kanzler S, Vieth M, et al. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with no-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis. 2004;22:221-227.
12. Nakamura T, Shirakawa K, Masuyama H, et al. Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther. 2005;21(suppl 2):19-26.
13. Xue Y, Zhou LY, Lin SR, et al. The application of high-resolution endoscopy in non-erosive reflux disease. Zhonghua Nei Ke Za Zhi. 2006;45:389-392.
14. Tack J, Janssens J. Functional Heartburn. Curr Treat Options Gastroenterol. 2002;5:251-258.
15. Quigley EM. Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation. Chin J Dig Dis. 2006;7:186-190.
16. Galmiche JP, Clouse RE, Balint A, et al. Functional esophageal disorders. Gastroenterology. 2006;130:1459-1465.
17. Fujiwara Y, Higuchi K, Shiba M, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol. 2005;100:754-758.
18. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol. 2004;99:1652-1656.
19. Zentilin P, Savarino V, Mastracci L, et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol. 2005;100:2299-2306.
20. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
21. Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol. 2006;101:1084-1091.
22. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981-988.
23. Yoshida N, Uchiyama K, Kuroda M, et al. Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol. 2004;39:816-822.
24. Keohane J, Quigley EM. Functional dyspepsia: the role of visceral hypersensitivity in its pathogenesis. World J Gastroenterol. 2006;12:2672-2676.
25. Quigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol. 2004;18:695-706.
26. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastrooesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7-12.
27. Shi G, des Varannes SB, Scarpignato C, et al. Reflux related symptoms in patients with normal esophageal exposure to acid. Gut. 1995;37:457-464.
28. Bhalla V, Liu J, Puckett JL, et al. Symptom hypersensitivity to acid infusion is associated with hypersensitivity of esophageal contractility. Am J Physiol Gastrointest Liver Physiol. 2004;287: G65-G71.
29. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005;128:771-778.
30. Caviglia R, Ribolsi M, Maggiano N, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol. 2005;100:543-548.
31. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructure alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol. 2005;100:537-542.
32. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885-892.
33. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. Am J Gastroenterol. 2005;100: 1477-1488.
34. van Zanten SV, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial. Am J Gastroenterol. 2006;101: 2096-2106.
35. Bruley Des Varannes S, Marek L, Humeau B, et al. Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and Quality of Life of patients. Gastroenterol Clin Biol. 2006;30: 364-370.
36. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol. 2006;101: 18-28.
37. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastrooesophageal reflux disease without oesophagitis. Gut. 1991;32: 845-848.
38. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three-year follow-up of patients with gastro-esophageal reflux disease. Gut. 1992;33:1016-1019.
39. Ollyo JB, Monnier P, Fontolliet C, et al. The natural history, prevalence and incidence of reflux oesophagitis. Gullet. 1993;3(suppl):3-10.
40. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long-term outcome in gastro-oesophageal reflux disease: six-year follow-up of 107 patients. Gut. 1994;35:8-14.
41. Trimble KC, Douglas S, Pryde A, et al. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci. 1995;40:1098-1104.
42. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux esophagitis: a 10-year follow-up of patient symptomatology and quality of life. Gut. 1996;38:491-486.
43. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastro-oesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
44. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol. 1997;9:1161-1167.
45. McDougall NI, Johnston BT, Collins JS, et al. Three to 4.5 year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998;33:1016-1022.
46. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol. 2006;101:2457-2462.
47. Fullard M, Kang JY, Neild P, et al. Systematic review: does gastrooesophageal reflux disease progress? Aliment Pharmacol Ther. 2006;24:33-45.
48. Quera R, O'Sullivan K, Quigley EM. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Endoscopy. 2006;38: 162-169.